Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2021-12, Vol.23 (12), p.2660-2669
• Main Authors: Home, Philip D., Mehta, Roopa, Hafidh, Khadija A. S., Gurova, Olesya Y., Alvarez, Agustina, Serafini, Paul, Pourrahmat, Mir‐Masoud
• Format: Article
• Language: English
• Subjects: Adverse events; Bayesian analysis; Blood Glucose; Clinical outcomes; Clinical trials; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug Combinations; GLP-1 receptor agonists; GLP‐1 analogue; Glucagon; Glycated Hemoglobin A - analysis; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Insulin; Insulin Glargine; insulin therapy; Intolerance; Literature reviews; Meta-analysis; network meta‐analysis; Original; type 2 diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14518

Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of basal insulin glargine 100 U/mL and lixisenatide (glucagon‐like peptide‐1 receptor agonist) versus IDegAsp, a co‐formulation of basal insulin degludec 100 U/mL with rapid‐acting insulin aspart. Materials and Methods A systematic literature search of randomized controlled trials (RCTs) was performed. Outcomes from eligible RCTs were compared by an indirect treatment comparison using a Bayesian framework. Subanalyses of Japanese and international trials were performed. Results Eight RCTs (duration 26‐30 weeks) were included. Mean difference in HbA1c change with iGlarLixi exceeded that for IDegAsp: −0.64 (95% credible interval −1.01, −0.28) %‐units (−7.0 [−11.0, −3.1] mmol/mol) for all trials, −0.39 (−0.55, −0.23) %‐units (−4.3 [−6.0, −2.5] mmol/mol) for international, and −0.88 (−1.11, −0.64) %‐units (−9.6 [−12.1, −7.0] mmol/mol) for Japanese trials. HbA1c target achievement (